Hartman Institute for Therapeutic Organ Regeneration

Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.

TitleBeta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.
Publication TypeJournal Article
Year of Publication2014
AuthorsNociari MM, Lehmann GL, Bay AEPerez, Radu RA, Jiang Z, Goicochea S, Schreiner R, J Warren D, Shan J, de Beaumais SAdam, Ménand M, Sollogoub M, Maxfield FR, Rodriguez-Boulan E
JournalProc Natl Acad Sci U S A
Volume111
Issue14
PaginationE1402-8
Date Published2014 Apr 08
ISSN1091-6490
KeywordsAnimals, beta-Cyclodextrins, Binding Sites, Chromatography, High Pressure Liquid, Computer Simulation, Fluorescence, In Vitro Techniques, Lipofuscin, Mice, Mice, Knockout, Oxidation-Reduction, Retinal Pigment Epithelium, Retinoids
Abstract

<p>Accumulation of lipofuscin bisretinoids (LBs) in the retinal pigment epithelium (RPE) is the alleged cause of retinal degeneration in genetic blinding diseases (e.g., Stargardt) and a possible etiological agent for age-related macular degeneration. Currently, there are no approved treatments for these diseases; hence, agents that efficiently remove LBs from RPE would be valuable therapeutic candidates. Here, we show that beta cyclodextrins (β-CDs) bind LBs and protect them against oxidation. Computer modeling and biochemical data are consistent with the encapsulation of the retinoid arms of LBs within the hydrophobic cavity of β-CD. Importantly, β-CD treatment reduced by 73% and 48% the LB content of RPE cell cultures and of eyecups obtained from Abca4-Rdh8 double knock-out (DKO) mice, respectively. Furthermore, intravitreal administration of β-CDs reduced significantly the content of bisretinoids in the RPE of DKO animals. Thus, our results demonstrate the effectiveness of β-CDs to complex and remove LB deposits from RPE cells and provide crucial data to develop novel prophylactic approaches for retinal disorders elicited by LBs.</p>

DOI10.1073/pnas.1400530111
Alternate JournalProc Natl Acad Sci U S A
PubMed ID24706818
PubMed Central IDPMC3986126
Grant ListR21 EY022165 / EY / NEI NIH HHS / United States
EY022165 / EY / NEI NIH HHS / United States
R01 EY008538 / EY / NEI NIH HHS / United States
P30 EY000331 / EY / NEI NIH HHS / United States
EY08538 / EY / NEI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065